Refining the Quality of Monoclonal Antibodies: Grafting Unique Peptide-Binding Site in the Fab Framework.

Jeremy D King, John C Williams

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jeremy D KingDepartment of Molecular Medicine, Beckman Research Institute at City of Hope, Duarte, CA, USA.

John C WilliamsDepartment of Molecular Medicine, Beckman Research Institute at City of Hope, Duarte, CA, USA. jcwilliams@coh.org.

Funding

In situ Imaging of CAR T-cellsR21CA193055 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BROWN, CHRISTINE, WILLIAMS, JOHN CHARLES · 2015 to 2017

$740k

NCI NIH HHS R21 CA193055

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are a major therapeutic modality. Grafting the meditope binding site onto mAbs, also known as meditope-enabling, can extend the usefulness of mAbs by providing an additional protein-protein interaction surface without altering the stability or antigen binding. We have previously used this site for attaching dyes, cytotoxic drugs, and entire proteins. Here, we provide a simple protocol for meditope-enabling mAbs, and verifying meditope and antigen binding using flow cytometry (FACS).

Indexed as

Amino Acid SequenceAntibodies, MonoclonalBinding SitesComputational BiologyHumansImmunoglobulin Fab FragmentsMutationProtein BindingProtein EngineeringStructure-Activity RelationshipAntibodies, MonoclonalImmunoglobulin Fab FragmentsAntibody-drug conjugateBispecific antibodyMeditope

Identifiers

PMID30539475

DOI10.1007/978-1-4939-8958-4_12

PMCPMC6827484

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.